Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Substance Policy topic
No spam. Unsubscribe anytime.
Senators hear split testimony on proposed kratom ban; sponsor cites health risks, users describe benefits
Summary
SB 262 would ban kratom sales in Delaware; testimony split between family members and public‑health witnesses who tied kratom to harms and deaths, and users and health advocates who urged regulation to preserve access for those who report benefits.
Senator Hoffner opened the committee’s discussion of SB 262 by urging the committee to consider a ban on kratom sales in Delaware, describing kratom as an unregulated, opioid‑receptor‑acting product that federal and state health agencies have flagged for safety concerns.
"Kratom is unregulated. It is an opiate‑like substance being sold today in gas stations, vape shops and convenience stores with no age verification, no product standards, and no oversight," Senator Hoffner said, citing reports of liver injury, seizures and deaths where kratom was a contributing factor.
Public comment and witnesses reflected a sharp divide. Several users and veterans described long‑term use of whole‑leaf kratom for chronic pain, insomnia or recovery from opioid dependence and urged regulation rather than prohibition. Melody Wolf, a chronic‑pain patient and long‑time kratom user invited to speak at an HHS/FDA forum, argued that whole‑leaf kratom had helped her function: "For me, this is not theoretical. If I lose access, I risk going backward into pain," she said.
Other speakers described personal tragedies they attributed to kratom. Dan Gibbs, a father whose son died in 2023, told the committee the coroner attributed intoxication by kratom as the cause of death and urged a ban. "The primary psychoactive act... was kratom. No other substances were in his blood stream," he said.
Sponsor and agency supporters said that product variability and synthetic derivatives complicate attempts to regulate the market reliably. Senator Hoffner said she would work to remove criminal penalties for simple possession from the draft and focus enforcement on sales, age restrictions and dangerous synthetics. The Office of Defense Services and other witnesses urged avoiding criminalization of personal possession and recommended narrow, targeted drafting.
The committee limited public comment to brief remarks because of a long agenda. Lawmakers asked staff and witnesses for further technical drafting on distinguishing synthetic derivatives from whole‑leaf kratom, mechanisms for age gating and product testing if regulation — rather than prohibition — were pursued. No committee vote was recorded.
